CPBTD
NVCR icon

Central Pacific Bank - Trust Division’s NovoCure NVCR Stock Holding History

Central Pacific Bank - Trust Division’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-5
Closed -$76 – 900
2026
Q2 		$76 Buy
+5
New +$76 ﹤0.01% 880

Other funds holding NVCR

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Central Pacific Bank - Trust Division's NVCR Position: Q3 2026 in Review

Central Pacific Bank - Trust Division sold out of NovoCure (NVCR) in Q3 2026, closing a stake of 5 shares — an estimated $76 sold.

Central Pacific Bank - Trust Division first reported a position in NVCR in Q2 2026 and held it in 1 quarter. The position peaked at $76 in Q2 2026. 15 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

  • Central Pacific Bank - Trust Division reported no remaining NovoCure position as of Q3 2026 after selling out during the quarter.
  • Central Pacific Bank - Trust Division sold 5 NovoCure shares in Q3 2026, an estimated $76.
  • Central Pacific Bank - Trust Division first reported a position in NovoCure in Q2 2026 and held it in 1 quarter.
  • Central Pacific Bank - Trust Division's NovoCure position peaked at $76 in Q2 2026.
  • 15 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on Central Pacific Bank - Trust Division's 13F filing for Q3 2026, filed 6 Oct 2026.